Pharma
-
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
By Michael Gibney • Oct. 22, 2024 -
PharmaVoice 100
2024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
By Meagan Parrish • Oct. 22, 2024 -
Trendline
Commercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.
By Amy Baxter • Oct. 21, 2024 -
Sponsored by CareMetx
Embedding into the provider’s workflow is key to a specialty drug’s success
Providers struggle with time-consuming processes. Patients are waiting for therapy. Embedded EMR system solutions can streamline therapy initiation and improve outcomes.
By Michael Sullivan, President of Provider Solutions at CareMetx • Oct. 21, 2024 -
PharmaVoice 100
2024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
By Amy Baxter • Oct. 18, 2024 -
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
As new Alzheimer’s biomarkers come into play, here’s where the money is going
The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.
By Michael Gibney • Oct. 17, 2024 -
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
By Alexandra Pecci • Oct. 16, 2024 -
PharmaVoice 100
2024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.
By Meagan Parrish • Oct. 16, 2024 -
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
By Michael Gibney • Oct. 15, 2024 -
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
By Jonathan Gardner • Oct. 15, 2024 -
As election day nears, Trump and Harris veer in different directions on pharma
The two presidential candidates have developed diverging policies related to healthcare and pharma.
By Amy Baxter • Oct. 14, 2024 -
Will a Medicare boost propel digital therapeutics to the mainstream?
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
By Kelly Bilodeau • Oct. 14, 2024 -
PharmaVoice 100
2024 PharmaVoice 100s: Standout Leaders
Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.
By Meagan Parrish • Oct. 14, 2024 -
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
By Amy Baxter • Oct. 10, 2024 -
Q&A
‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
By Alexandra Pecci • Oct. 9, 2024 -
As AI transforms drug development, biotechs might not need as much Big Pharma support
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
By Amy Baxter • Oct. 9, 2024 -
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
By Kelly Bilodeau • Oct. 7, 2024 -
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help.
By Michael Gibney • Oct. 3, 2024 -
How Roche plans to fill a projected $8B sales gap
Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.
By Amy Baxter • Oct. 2, 2024 -
Top pharma and biotech conferences 2025
Mark your calendars for the most important industry conferences in 2025.
By Michael Gibney • Oct. 1, 2024 -
Q&A
California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Sponsored by Hexagon
Why today’s leading pharma manufacturers are adopting proactive asset management strategies
In recent months, high-profile drug shortages have brought pharmaceutical manufacturing operations into the spotlight.
Sept. 30, 2024